title: Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy.
abstract: OBJECTIVE
  To compare total medical costs and utilization over a 12-month period in commercially insured patients receiving FDA-approved adjunctive atypical antipsychotics (aripiprazole, olanzapine, or quetiapine) for depression.
  
  
  METHODS
  A retrospective claims analysis was conducted from 2005-2010 using the PharMetrics database. Subjects were adult commercial health-plan members with depression, identified using International Classification of Diseases codes and followed for 12 months after augmentation with an atypical antipsychotic. Outcomes included total medical costs, hospitalization, and ER visits. Generalized linear models and logistic regression were used to compare the total medical costs and the odds of hospitalization and ER visits between the treatment groups after adjusting for baseline demographic and clinical characteristics.
  
  
  RESULTS
  A total of 9675 patients with depression were included in the analysis, of which 68.4% were female, with a mean age of 45.2 (±12.0) years. Adjusted 12-month total medical costs were higher for olanzapine ($14,275) and quetiapine ($12,998) compared to aripiprazole ($9,801; P < 0.05 for all comparisons with aripiprazole). When divided into inpatient and outpatient costs, olanzapine and quetiapine had significantly higher adjusted inpatient costs compared to aripiprazole ($6,124 and $4,538 vs $2,976, respectively; P < 0.05 for all comparisons with aripiprazole). Similar results were seen for adjusted outpatient costs. Adjusted odds of hospitalization for olanzapine (odds ratio [OR] = 1.73; 95% CI confidence interval [CI] = 1.42-2.10) and quetiapine (OR = 1.40; 95% CI = 1.21-1.60) were significantly higher than aripiprazole at 12 months. The adjusted odds of an ER visit for olanzapine (OR = 1.40; 95% CI = 1.18-1.65) and quetiapine (OR = 1.62; 95% CI = 1.44-1.81) were also significantly higher compared to aripiprazole at 12 months.
  
  
  CONCLUSIONS
  In commercially insured major depressive disorder patients, olanzapine and quetiapine were associated with higher total medical costs, the difference being primarily attributable to higher inpatient costs. Additionally, olanzapine and quetiapine were associated with significantly higher odds of hospitalization and ER visits compared to aripiprazole.
authors: Bristol-Myers Squibb, Plainsboro, NJ, USA.
authors: Anagha
authors: A
authors: Nadkarni
authors: Iftekhar
authors: I
authors: Kalsekar
authors: Min
authors: M
authors: You
authors: Robert
authors: R
authors: Forbes
authors: Tony
authors: T
authors: Hebden
keywords: adjunctive therapy; atypical antipsychotics; depression
references: J Clin Psychiatry. 2002 Nov;63(11):963-71
references: 12444808
references: Psychiatr Serv. 2009 Sep;60(9):1175-81
references: 19723731
references: J Clin Epidemiol. 1992 Jun;45(6):613-9
references: 1607900
references: Ann Pharmacother. 2012 May;46(5):642-9
references: 22550279
references: Drugs. 2011 Jan 1;71(1):43-64
references: 21175239
references: Med Care. 1989 May;27(5):543-57
references: 2498585
references: Science. 1996 Nov 1;274(5288):740-3
references: 8966556
references: J Clin Psychiatry. 2004 Mar;65(3):341-7
references: 15096073
references: J Clin Psychiatry. 2002 Aug;63(8):717-26
references: 12197453
references: Biol Psychiatry. 2003 Apr 15;53(8):649-59
references: 12706951
references: Pharmacoeconomics. 2004;22(6):363-73
references: 15099122
references: J Clin Psychiatry. 2005;66 Suppl 8:13-21
references: 16336032
references: Am J Manag Care. 2010 May;16(5):370-7
references: 20469957
references: Curr Med Res Opin. 2010 Oct;26(10):2475-84
references: 20825269
references: Clin Ther. 2011 Sep;33(9):1246-57
references: 21840058
references: J Clin Psychopharmacol. 2005 Aug;25(4):336-41
references: 16012276
references: J Clin Psychiatry. 2003 Dec;64(12):1465-75
references: 14728109
references: J Med Econ. 2012;15(1):105-11
references: 21991926
references: Am J Psychiatry. 2006 Nov;163(11):1905-17
references: 17074942
references: Curr Psychiatry Rep. 2008 Dec;10(6):481-6
references: 18980731
references: JAMA. 2003 Jun 18;289(23):3095-105
references: 12813115